Clinical trials: Hyperhidrosis
Primary Axillary Hyperhidrosis
Evaluation of N-SWEAT Patch for Treatment of Primary Axillary Hyperhidrosis or Excessive Axillary Sweating
The Sahara Study is a study to evaluate the safety and effectiveness of the N-SWEAT Patch for use in subjects with excessive axillary sweating, or primary focal axillary hyperhidrosis.
- Trial name
- NCT04599907
- Testing
- Roll-In Cohort: Single Application of N-SWEAT Patch, Randomized Cohort: Single Application of N-SWEAT Patch
- Where
- 9 sites in United States
- Volunteers
- 120 people
- Sponsor
- Candesant Biomedical, Inc.
Hyperhidrosis
A Dose-Ranging Study of the Effect of Glycopyrrolate in Subjects With Axillary Hyperhidrosis
The purpose of this study is to evaluate the safety and efficacy of glycopyrrolate compared to vehicle for the treatment of axillary hyperhidrosis.
- Trial name
- NCT02016885
- Testing
- glycopyrrolate, 1.0%, glycopyrrolate, 2.0%, glycopyrrolate, 3.0%
- Where
- 21 sites in United States
- Volunteers
- 198 people
- Sponsor
- Journey Medical Corporation
Hyperhidrosis
A Study to Evaluate Clinical Effect, Pharmacokinetics , Safety, and Tolerability of Umeclidinium in Palmar Hyperhidrosis Subjects
Umeclidinium (UMEC) is a potent pan-active long-acting muscarinic antagonist (LAMA). It is anticipated that topical administration of UMEC will block stimulation of muscarinic receptors, thereby reducing the overproduction of…
- Trial name
- NCT02673619
- Testing
- Umeclidinium, Vehicle
- Where
- 6 sites in United States, Canada
- Volunteers
- 58 people
- Sponsor
- Stiefel, a GSK Company
Hyperhidrosis
Clinical Trial To Evaluate ANT-1207 In Participants With Primary Axillary Hyperhidrosis
The purpose of this study is to establish the therapeutic range of ANT-1207 in the treatment of primary axillary hyperhidrosis.
- Trial name
- NCT02479139
- Testing
- Vehicle, ANT-1207
- Where
- 19 sites in United States
- Volunteers
- 145 people
- Sponsor
- Allergan
Hyperhidrosis
A Non-Interventional Study To Assess Sweating
To evaluate the gravimetric sweat measurements in subjects who meet the subjective criteria for a diagnosis of palmar hyperhidrosis compared to subjects without hyperhidrosis.
- Trial name
- NCT02552199
- Testing
- gravimetric
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Botanix Pharmaceuticals
Primary Axillary Hyperhidrosis
A Safety Study of BBI-4000 Gel in Patients With Axillary Hyperhidrosis
Hyperhidrosis is a disorder of abnormal excessive sweating. Primary hyperhidrosis (armpits, hands, and feet) affects approximately 4.8% of the US population and is believed to be caused by an overactive cholinergic response of…
- Trial name
- NCT03627468
- Testing
- Sofpironium Bromide Gel, 5%, Sofpironium Bromide Gel, 15%
- Where
- 12 sites in United States
- Volunteers
- 300 people
- Sponsor
- Botanix Pharmaceuticals
Hyperhidrosis
Study of Glycopyrronium in Subjects With Axillary Hyperhidrosis
The study is a randomized, double-blind, vehicle controlled, parallel group study, designed to assess the efficacy and safety of glycopyrronium topical wipes, once daily, compared to vehicle in subjects with axillary…
- Trial name
- NCT02530294
- Testing
- glycopyrronium Topical Wipes, Vehicle
- Where
- 20 sites in United States
- Volunteers
- 353 people
- Sponsor
- Journey Medical Corporation
Primary Axillary Hyperhidrosis
A Safety Study of BBI-4000 Gel in Pediatric Patients With Axillary Hyperhidrosis
Hyperhidrosis is a disorder of abnormal excessive sweating. Primary hyperhidrosis (armpits, hands, and feet) affects approximately 4.8% of the US population and is believed to be caused by an overactive cholinergic response of…
- Trial name
- NCT03785587
- Testing
- Sofpironium Bromide Gel, 15%
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Botanix Pharmaceuticals
Hyperhidrosis
A Safety and Efficacy Study of BBI-4000 in Subjects With Axillary Hyperhidrosis
To assess the safety and efficacy of 3 doses of BBI-4000 and vehicle (4 treatment arms), when applied once a day for 4 weeks, for the treatment of axillary hyperhidrosis.
- Trial name
- NCT02336503
- Testing
- BBI-4000 Gel, 5%, BBI-4000 Gel, 10%, BBI-4000 Gel, 15%
- Where
- 12 sites in United States
- Volunteers
- 189 people
- Sponsor
- Botanix Pharmaceuticals
Axillary Hyperhidrosis
Safety and Efficacy Study of Sofpironium Bromide in Subjects With Axillary Hyperhidrosis (BBI-4000-CL-302)
Hyperhidrosis is a disorder of abnormal excessive sweating. Primary hyperhidrosis (armpits, hands, and feet) affects approximately 4.8% of the US population and is believed to be caused by an overactive cholinergic response of…
- Trial name
- CARDIGANII (NCT03948646)
- Testing
- Sofpironium Bromide, 15%, Vehicle
- Where
- 42 sites in United States
- Volunteers
- 351 people
- Sponsor
- Botanix Pharmaceuticals
Hyperhidrosis
GSK1358820 (Botulinum Toxin A) PhIII DB & OL Study in Patients With Axillary Hyperhidrosis
The primary objective of this study is to demonstrate superiority of single treatment of GSK1358820 (hereinafter, referred to as BOTOX®) over placebo in terms of the efficacy of treatment with BOTOX® 50 U in each axilla (100 U in…
- Trial name
- NCT01128738
- Testing
- GSK1358820
- Where
- 14 sites in Japan
- Volunteers
- 152 people
- Sponsor
- GlaxoSmithKline
Hyperhidrosis
Comparator Study of the Effect of Glycopyrrolate and Glycopyrronium in Subjects With Axillary Hyperhidrosis
The purpose of the study is to assess the safety of 2 doses of glycopyrrolate compared to 2 doses of glycopyrronium and vehicle (5 treatment arms) for the treatment of axillary hyperhidrosis when applied once daily for 4 weeks…
- Trial name
- NCT02129660
- Testing
- Dose 1 of glycopyrrolate, 2.0% QD, Dose 2 of glycopyrrolate, 3.0% QD, Dose 1 of glycopyrronium, 2.5% QD
- Where
- 15 sites in United States, Canada
- Volunteers
- 105 people
- Sponsor
- Journey Medical Corporation
Hyperhidrosis
Evaluation of 1440nm Laser Assisted Selective Photothermolysis for Treatment of Axillary Hyperhidrosis
The purpose of this study is to evaluate the safety and efficacy of the Nd:YAG 1440 nm wavelength laser for the treatment of primary hyperhidrosis of the axilla.
- Trial name
- NCT02100072
- Testing
- Nd:YAG 1440 nm laser
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Cynosure, Inc.
Palmar Hyperhidrosis
A Study of Glycopyrronium Cloth, 2.4% in Patients With Palmar Hyperhidrosis
The objective of this study is to assess the efficacy and safety of glycopyrronium cloth, 2.4% when used to treat palmar hyperhidrosis.
- Trial name
- NCT03880266
- Testing
- Glycopyrronium cloth, 2.4%, Vehicle
- Where
- 7 sites in United States
- Volunteers
- 72 people
- Sponsor
- Journey Medical Corporation
Axillary Hyperhidrosis
Safety and Efficacy Study of Sofpironium Bromide in Subjects With Axillary Hyperhidrosis (BBI-4000-CL-301)
Hyperhidrosis is a disorder of abnormal excessive sweating. Primary hyperhidrosis (armpits, hands, and feet) affects approximately 4.8% of the US population and is believed to be caused by an overactive cholinergic response of…
- Trial name
- CardiganI (NCT03836287)
- Testing
- Sofpironium Bromide Gel, 15%, Vehicle
- Where
- 39 sites in United States
- Volunteers
- 350 people
- Sponsor
- Botanix Pharmaceuticals
Hyperhidrosis
Pharmacokinetic, Safety, Tolerability, and Clinical Effect of Topical Umeclidinium in Primary Axillary Hyperhidrosis
This is a double blind (sponsor unblind), repeat dose, randomized, parallel group, placebo controlled study to assess the pharmacokinetic parameters, safety, tolerability, and clinical effect of topically applied umeclidinium…
- Trial name
- NCT02563899
- Testing
- Umeclidinium, Vehicle
- Where
- 3 sites in United States, Canada
- Volunteers
- 28 people
- Sponsor
- GlaxoSmithKline
Hyperhidrosis
A Safety, Tolerability and Preliminary Efficacy Study of BBI-4000 Gel in Subjects With Palmar Hyperhidrosis
To assess the safety and local tolerability of BBI-4000 15% gel compared with vehicle (placebo) when applied topically once daily in subjects with palmar hyperhidrosis.
- Trial name
- NCT02682238
- Testing
- BBI-4000, 15%, Vehicle gel
- Where
- 5 sites in United States
- Volunteers
- 50 people
- Sponsor
- Botanix Pharmaceuticals
Hyperhidrosis
A Confirmatory Safety and Efficacy Study of BBI-4000 in Subjects With Axillary Hyperhidrosis
This study is being conducted to assess the safety and efficacy of 3 concentrations of BBI-4000 and vehicle (4 treatment arms), applied for the treatment of axillary hyperhidrosis.
- Trial name
- NCT03024255
- Testing
- BBI-4000 gel, 5%, BBI-4000 gel, 10%, BBI-4000 gel, 15%
- Volunteers
- 227 people
- Sponsor
- Botanix Pharmaceuticals
HYPERHIDROSIS
Investigation of Hyperhidrosis Treatment Using the Nd: YAG 1440nm Wavelength Laser
The purpose of this study is to evaluate the safety and efficacy of the Nd:YAG 1440 nm wavelength laser for the treatment of primary hyperhidrosis of the axilla.
- Trial name
- NCT01810991
- Testing
- Nd:YAG Laser
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Cynosure, Inc.
Hyperhidrosis
Long-term Safety Study of Glycopyrronium in Subjects With Primary Axillary Hyperhidrosis
This is an open-label, long-term safety study of glycopyrronium topical wipes, enrolling up to 660 subjects with primary axillary hyperhidrosis who participated in either the DRM04-HH04 or DRM04-HH05 studies.
- Trial name
- NCT02553798
- Testing
- Glycopyrronium Topical Wipes
- Where
- 48 sites in United States, Germany
- Volunteers
- 564 people
- Sponsor
- Journey Medical Corporation